US 11957677
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
granted A61KA61K31/496A61K31/5025
Quick answer
US patent 11957677 (Cancer treatment using FGFR inhibitors and PLK1 inhibitors) held by Cardiff Oncology, Inc. expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Cardiff Oncology, Inc.
- Grant date
- Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/496, A61K31/5025, A61K31/506, A61K31/517